Direct inference and control of genetic population structure from RNA sequencing data
Muhamad Fachrul(Baker Heart and Diabetes Institute), Michael Inouye(British Heart Foundation), Louise M. Judd(The University of Melbourne), Maheshwar Ghimire(Patan Academy of Health Sciences), Christiane Dolecek(Mahidol University), Agus Salim(Baker Heart and Diabetes Institute), Mila Shakya, Maurice Mbewe, Tran Do Hoang Nhu, Thomas C. Darton(Sheffield Teaching Hospitals NHS Foundation Trust), Tikhala Makhaza Jere, Trinh Van Tan(The University of Melbourne), James Meiring, Stephen Baker(University of Connecticut), Tran Vu Thieu Nga(Oxford University Clinical Research Unit), Robert S. Heyderman(University of Liverpool), Harrison Msuku, John D. Clemens(International Vaccine Institute), Abhilasha Karkey(Nepal Development Research Institute), Rose Nkhata, Yu-Han Kao(University of Liverpool), Sarah J. Dunstan(The University of Melbourne), Farhana Khanam, Clemens Masesa(University of Liverpool), Christoph J. Blohmke, Andrew J. Pollard(University of Oxford), Melita A. Gordon(University of Liverpool), Moses Kamzati(University of Liverpool), Taylor Harshegyi(The Alfred Hospital), Kar Seng Sim(The University of Sydney), Buddha Basnyat(University of Washington), Rajendra Shrestha(Patan Academy of Health Sciences), Kathryn E. Holt(London School of Hygiene & Tropical Medicine), Chiea Chuen Khor(Agency for Science, Technology and Research), Jennifer Hill(University of Oxford), Merryn Voysey(Stratasys (Israel)), Deus Thindwa(Yale University), Virginia E. Pitzer(Yale University), Patrick Munthali(University of Liverpool), Anup Adhikari(Patan Academy of Health Sciences), Firdausi Qadri(International Centre for Diarrhoeal Disease Research), Susan Tonks(University of Oxford), Neil J. Saad, Happy Banda, Gordon Dougan(University of Cambridge), Sabina Dongol(Patan Academy of Health Sciences)
Cited by 12
Related Papers
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
|The Lancet|2022|16k
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k